InFectious Disease
Our Technology
Inflammatory Disease

our medicinesSave Lives

Ventria Bioscience’s internal therapeutic pipeline is focused on safely improving clinical outcomes in infectious disease and inflammatory disease.

Ven 120
Ven Beta

the VentriaTEAM

Our people and our company are driven by the scientific method and by our vision of improving longevity and quality of life for people all over the globe.

Every day, our talented scientists, entrepreneurs, and advisors work together with a sense of urgency and commitment.

Our Research Partners

Bill & Melinda Gates Foundation

In 2017, Ventria Bioscience received a $4.2 million grant from the Bill & Melinda Gates Foundation to fund development of efficient biomanufacturing for new therapeutics targeting Enterotoxigenic Escherichia coli

Children’s Hospital Colorado and University of Colorado School of Medicine

Ventria Bioscience has been engaged in a multi-year collaboration with the research group of Edwin de Zoeten, MD, PhD (Children’s Hospital Colorado and University of Colorado School of Medicine) to investigate the mechanisms by which Ventria’s lead candidate, VEN120—the principal component of which is lactoferrin—reduces inflammation in preclinical models of inflammatory bowel disease (IBD).

Johns Hopkins School of Medicine

Ventria Bioscience is currently engaged in an active clinical research collaboration with Jeremy Walston, MD, and colleagues at the Johns Hopkins School of Medicine. This Phase 2, randomized, controlled clinical trial, Effects of rhLactoferrin on Chronic Inflammation in the Elderly (ELCIE), is designed to investigate how recombinant human lactoferrin (rhLF) produced and purified from rice grain may improve mobility and memory versus placebo in up to 60 older adults with chronic inflammation.

UC Davis

In collaboration with Dr. Bo Lonnerdal at University of California, Davis and Dr. Nelly Zavaleta at Children’s Hospital in Lima, Peru, Ventria Bioscience sponsored a double-blind, randomized controlled clinical study to investigate the ability of ExpressTec-made breastmilk proteins to reduce symptoms in 140 children with acute diarrhea.

University of Minnesota

Ventria Bioscience has previously collaborated with Jason Baker, MD, MS at the University of Minnesota/Hennepin County Medical Center on a pilot clinical trial, Recombinant Human Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients: A pilot study.

Our Blog: In Context

Design and Objectives of the ELCIE Clinical Trial

Effects of rhLactoferrin on Chronic Inflammation in the Elderly: Design and Objectives of the ELCIE Clinical Trial We have previously introduced an ongoing clinical study, headed by principal investigator Jeremy Walston MD of the Johns Hopkins School of Medicine, aimed at finding out if recombinant human lactoferrin (rhLactoferrin) produced from Ventria Bioscience’s ExpressTec biologic manufacturing […]